The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study.

ABSTRACT:

Background

Deutetrabenazine is approved in the USA, China, Australia, Israel, Brazil, and South Korea for the treatment of chorea associated with Huntington disease.

Objective

We aimed to evaluate the long-term safety and tolerability of deutetrabenazine for the treatment of Huntington disease.

Methods

This open-label, single-arm, multi-center study included patients who completed a double-blind study (Rollover) and patients who converted overnight from a stable tetrabenazine dose (Switch). Exposure-adjusted incidence rates (adverse events per person-year) were calculated. Efficacy was analyzed using a stable post-titration timepoint (8 weeks). Changes in the Unified Huntington's Disease Rating Scale total motor score and total maximal chorea score from baseline to we

SUBMITTER: Frank S 

PROVIDER: S-EPMC9653309 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature